(Q37851992)

24 August 2017

1 reference

title

Update on new drugs in small cell lung cancer (English)

1 reference

24 August 2017

1 reference

Leora Horn

1

1 reference

24 August 2017

Emily Louise Castellanos

series ordinal

2

1 reference

24 August 2017

David H Johnson

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 April 2011

1 reference

Expert Opinion on Investigational Drugs

24 August 2017

published in

1 reference

24 August 2017

volume

20

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

441-445

1 reference

24 August 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Small cell lung cancer: state-of-the-art therapy in 1996.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

VP-16 and cisplatin as first-line therapy for small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Small cell lung carcinoma (SCLC): the angiogenic phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Kinase inhibition with BAY 43-9006 in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Matrix metalloproteinases: biologic activity and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the Europea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

The Bcl-2 apoptotic switch in cancer development and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

ZD0473 treatment in lung cancer: an overview of the clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Expression and Prognostic Significance of Metalloproteinases and Their Tissue Inhibitors in Patients With Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.553185

10.1517/13543784.2011.553185

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference